45.80
price down icon1.04%   -0.48
after-market 시간 외 거래: 45.80
loading
전일 마감가:
$46.28
열려 있는:
$46.05
하루 거래량:
1.19M
Relative Volume:
1.13
시가총액:
$2.76B
수익:
$45.48M
순이익/손실:
$169.95M
주가수익비율:
17.48
EPS:
2.62
순현금흐름:
$230.85M
1주 성능:
+1.71%
1개월 성능:
-13.01%
6개월 성능:
-0.35%
1년 성능:
+78.84%
1일 변동 폭
Value
$45.07
$46.97
1주일 범위
Value
$44.97
$48.32
52주 변동 폭
Value
$24.22
$60.60

Protagonist Therapeutics Inc Stock (PTGX) Company Profile

Name
명칭
Protagonist Therapeutics Inc
Name
전화
(510) 474-0170
Name
주소
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Name
직원
126
Name
트위터
Name
다음 수익 날짜
2024-11-04
Name
최신 SEC 제출 서류
Name
PTGX's Discussions on Twitter

PTGX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
PTGX
Protagonist Therapeutics Inc
45.80 2.76B 45.48M 169.95M 230.85M 2.62
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.52 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.49 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
595.70 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.75 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
229.22 26.16B 3.81B -644.79M -669.77M -6.24

Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-12-06 개시 BMO Capital Markets Outperform
2024-12-06 개시 Goldman Neutral
2024-11-05 개시 Wedbush Outperform
2024-09-24 개시 TD Cowen Buy
2024-09-09 개시 Truist Buy
2023-10-30 개시 CapitalOne Overweight
2023-05-25 재개 Jefferies Buy
2022-08-25 개시 JMP Securities Mkt Outperform
2022-02-11 개시 BTIG Research Buy
2021-10-12 업그레이드 JP Morgan Neutral → Overweight
2021-10-11 업그레이드 Northland Capital Market Perform → Outperform
2021-09-20 다운그레이드 JP Morgan Overweight → Neutral
2021-05-24 개시 JMP Securities Mkt Outperform
2021-05-24 개시 Northland Capital Outperform
2021-01-06 개시 JP Morgan Overweight
2020-12-16 개시 Piper Sandler Overweight
2020-09-18 재확인 H.C. Wainwright Buy
2020-07-15 개시 Jefferies Buy
2020-05-18 재확인 H.C. Wainwright Buy
2019-07-08 개시 H.C. Wainwright Buy
2019-05-09 업그레이드 Stifel Hold → Buy
2018-12-06 개시 Nomura Buy
2018-01-29 개시 Stifel Buy
2017-07-21 개시 BTIG Research Buy
모두보기

Protagonist Therapeutics Inc 주식(PTGX)의 최신 뉴스

pulisher
Apr 18, 2025

When the Price of (PTGX) Talks, People Listen - news.stocktradersdaily.com

Apr 18, 2025
pulisher
Apr 16, 2025

Protagonist Therapeutics Reports Granting of Inducement Award | PTGX Stock News - GuruFocus

Apr 16, 2025
pulisher
Apr 16, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 16, 2025
pulisher
Apr 16, 2025

Protagonist Awards 20,000 Stock Options to Key New Hire at $46.95 - Stock Titan

Apr 16, 2025
pulisher
Apr 15, 2025

The 4.2% return this week takes Protagonist Therapeutics' (NASDAQ:PTGX) shareholders five-year gains to 558% - simplywall.st

Apr 15, 2025
pulisher
Apr 11, 2025

Protagonist Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:PTGX - Benzinga

Apr 11, 2025
pulisher
Apr 11, 2025

Polycythemia Vera Market to Show Remarkable Growth Trends from - openPR.com

Apr 11, 2025
pulisher
Apr 11, 2025

BTIG maintains Buy on Protagonist Therapeutics stock, $82 target By Investing.com - Investing.com Canada

Apr 11, 2025
pulisher
Apr 10, 2025

Johnson & Johnson, Protagonist Tout Positive Results For Psoriasis Oral Pill Study - Benzinga

Apr 10, 2025
pulisher
Apr 10, 2025

Protagonist Therapeutics (PTGX) Unveils Promising Data for Psori - GuruFocus

Apr 10, 2025
pulisher
Apr 10, 2025

Revolutionary Once-Daily Pill Achieves Complete Skin Clearance in 75% of Teen Psoriasis Patients - Stock Titan

Apr 10, 2025
pulisher
Apr 02, 2025

Winners and wishers: 9 potential Bay Area drug approvals coming this yearSan Francisco Business Times - The Business Journals

Apr 02, 2025
pulisher
Apr 02, 2025

(PTGX) Investment Analysis - news.stocktradersdaily.com

Apr 02, 2025
pulisher
Mar 25, 2025

Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High? - Yahoo Finance

Mar 25, 2025
pulisher
Mar 23, 2025

Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025 - Bluefield Daily Telegraph

Mar 23, 2025
pulisher
Mar 22, 2025

Why Protagonist Therapeutics, Inc. (PTGX) Went Up on Monday - MSN

Mar 22, 2025
pulisher
Mar 21, 2025

Insider Sell: William Waddill Sells 4,000 Shares of Protagonist Therapeutics Inc (PTGX) - GuruFocus

Mar 21, 2025
pulisher
Mar 20, 2025

Protagonist Therapeutics Takeda To Lead Regulatory Strategy For Rusfertide In Polycythemia Vera NDA - MarketScreener

Mar 20, 2025
pulisher
Mar 20, 2025

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. With Losses of $100,000 to Contact the Firm - Business Wire

Mar 20, 2025
pulisher
Mar 19, 2025

Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's Why - MSN

Mar 19, 2025
pulisher
Mar 19, 2025

Protagonist Therapeutics director Waddill sells $217,000 in stock By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Protagonist Therapeutics director Waddill sells $217,000 in stock - Investing.com

Mar 19, 2025
pulisher
Mar 18, 2025

Analysts Mentions Growth Catalysts for Protagonist Therapeutics (PTGX) — Best Biotech Stock for 2025? - MSN

Mar 18, 2025
pulisher
Mar 18, 2025

These 10 biotech companies are changing how we discover new drugs and treat complex diseases - Fast Company

Mar 18, 2025
pulisher
Mar 18, 2025

Fast Company Ranks Protagonist Among Elite Biotech Innovators: 2 FDA Filings Coming - StockTitan

Mar 18, 2025
pulisher
Mar 16, 2025

D-Wave Quantum And IonQ Are Among Top Mid-Cap Stock Gainers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio? - Benzinga

Mar 16, 2025
pulisher
Mar 15, 2025

Is Protagonist Therapeutics, Inc. (PTGX) the Best Healthcare Stock For Long-Term Investment? - Insider Monkey

Mar 15, 2025
pulisher
Mar 15, 2025

Protagonist Therapeutics CFO Ali Asif sells $1.46 million in stock By Investing.com - Investing.com South Africa

Mar 15, 2025
pulisher
Mar 15, 2025

Protagonist Therapeutics’ chief medical officer sells $1.7 million in stock By Investing.com - Investing.com Canada

Mar 15, 2025
pulisher
Mar 14, 2025

Protagonist Therapeutics CFO Ali Asif sells $1.46 million in stock - Investing.com India

Mar 14, 2025
pulisher
Mar 14, 2025

Protagonist Therapeutics’ chief medical officer sells $1.7 million in stock - Investing.com

Mar 14, 2025
pulisher
Mar 14, 2025

Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $76.00 - Defense World

Mar 14, 2025
pulisher
Mar 14, 2025

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Purchased by Victory Capital Management Inc. - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out - MSN

Mar 13, 2025
pulisher
Mar 13, 2025

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Acquired by Bank of New York Mellon Corp - Defense World

Mar 13, 2025
pulisher
Mar 13, 2025

Protagonist Therapeutics’ SWOT analysis: promising pipeline drives stock outlook By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 12, 2025

Protagonist Therapeutics’ SWOT analysis: promising pipeline drives stock outlook - Investing.com

Mar 12, 2025
pulisher
Mar 12, 2025

Learn to Evaluate (PTGX) using the Charts - Stock Traders Daily

Mar 12, 2025
pulisher
Mar 12, 2025

Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $72.00 at BMO Capital Markets - Defense World

Mar 12, 2025
pulisher
Mar 12, 2025

Protagonist Therapeutics (NASDAQ:PTGX) Hits New 1-Year High on Analyst Upgrade - Defense World

Mar 12, 2025
pulisher
Mar 11, 2025

Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It (NASDAQ:PTGX) - Seeking Alpha

Mar 11, 2025
pulisher
Mar 11, 2025

Wedbush Adjusts Protagonist Therapeutics Price Target to $70 From $58, Maintains Outperform Rating - Marketscreener.com

Mar 11, 2025
pulisher
Mar 11, 2025

Protagonist Therapeutics Soars as Icotrokinra Drives Breakthroug - GuruFocus.com

Mar 11, 2025

Protagonist Therapeutics Inc (PTGX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
자본화:     |  볼륨(24시간):